First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy
Open Access
- 5 September 2014
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 99 (12), 1784-1791
- https://doi.org/10.3324/haematol.2014.109355
Abstract
The current treatment approach for severe aplastic anemia in children is based on studies performed in the 1980s, and updated evidence is required. We retrospectively compared the outcomes of children with acquired severe aplastic anemia who received immunosuppressive therapy within prospective trials conducted by the Japanese Childhood Aplastic Anemia Study Group or who underwent bone marrow transplantation from an HLA-matched family donor registered in the Japanese Society for Hematopoietic Cell Transplantation Registry. Between 1992 and 2009, 599 children (younger than 17 years) with severe aplastic anemia received a bone marrow transplant from an HLA-matched family donor (n=213) or immunosuppressive therapy (n=386) as first-line treatment. While the overall survival did not differ between patients treated with immunosuppressive therapy or bone marrow transplantation [88% (95% confidence interval: 86–90) versus 92% (90–94)], failure-free survival was significantly inferior in patients receiving immunosuppressive therapy than in those undergoing bone marrow transplantation [56% (54–59) versus 87% (85–90); Pversus 2000–2009). In multivariate analysis, age P=0.007), and choice of first-line immunosuppressive therapy was the only unfavorable factor for failure-free survival (P<0.0001). These support the current algorithm for treatment decisions, which recommends bone marrow transplantation when an HLA-matched family donor is available in pediatric severe aplastic anemia.Keywords
This publication has 40 references indexed in Scilit:
- Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groupsPublished by Ferrata Storti Foundation (Haematologica) ,2012
- Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemiaBlood, 2012
- Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic AnemiaNew England Journal of Medicine, 2011
- Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemiaHaematologica, 2011
- Decreased Infection-Related Mortality and Improved Survival in Severe Aplastic Anemia in the Past Two DecadesClinical Infectious Diseases, 2011
- Predicting response to immunosuppressive therapy in childhood aplastic anemiaHaematologica, 2011
- Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working partyPublished by Ferrata Storti Foundation (Haematologica) ,2010
- Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized studyHaematologica, 2009
- Long-Term Outcome of Pediatric Patients with Severe Aplastic Anemia Treated with Antithymocyte Globulin and CyclosporineThe Journal of Pediatrics, 2008
- Comparison between bone marrow transplantation and antithymocyte globulin in treatment of young patients with severe aplastic anemiaThe Journal of Pediatrics, 1984